Cara Therapeutic Stock Performance
| CARA Stock | USD 0.30 0.01 3.45% |
The firm shows a Beta (market volatility) of 1.14, which signifies a somewhat significant risk relative to the market. Cara Therapeutic returns are very sensitive to returns on the market. As the market goes up or down, Cara Therapeutic is expected to follow. At this point, Cara Therapeutic has a negative expected return of -0.0576%. Please make sure to confirm Cara Therapeutic's value at risk and the relationship between the kurtosis and price action indicator , to decide if Cara Therapeutic performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cara Therapeutic has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Cara Therapeutic is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:2 | Last Split Date 2014-01-16 |
1 | Wall Street SWOT Cara Therapeutics stock navigates pivotal phase in drug development - Investing.com | 09/27/2024 |
2 | Disposition of 2483 shares by Scott Terrillion of Cara Therapeutic at 3.51 subject to Rule 16b-3 | 10/28/2024 |
3 | Disposition of 3668 shares by Christopher Posner of Cara Therapeutic at 0.29 subject to Rule 16b-3 | 11/04/2024 |
4 | Cara Therapeutics CEO Posner sells shares worth 1,063 | 11/06/2024 |
5 | Cara Q3 Earnings Snapshot | 11/15/2024 |
| Begin Period Cash Flow | 64.1 M |
Cara |
Cara Therapeutic Relative Risk vs. Return Landscape
If you would invest 33.00 in Cara Therapeutic on September 1, 2024 and sell it today you would lose (3.00) from holding Cara Therapeutic or give up 9.09% of portfolio value over 90 days. Cara Therapeutic is currently does not generate positive expected returns and assumes 4.3784% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Cara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cara Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cara Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cara Therapeutic, and traders can use it to determine the average amount a Cara Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0132
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CARA |
Estimated Market Risk
| 4.38 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cara Therapeutic is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cara Therapeutic by adding Cara Therapeutic to a well-diversified portfolio.
Cara Therapeutic Fundamentals Growth
Cara Stock prices reflect investors' perceptions of the future prospects and financial health of Cara Therapeutic, and Cara Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cara Stock performance.
| Return On Equity | -1.84 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (16.36) % | ||||
| Current Valuation | (21.94 M) | ||||
| Shares Outstanding | 54.86 M | ||||
| Price To Earning | 62.54 X | ||||
| Price To Book | 23.59 X | ||||
| Price To Sales | 1.52 X | ||||
| Revenue | 20.97 M | ||||
| Gross Profit | (56.14 M) | ||||
| EBITDA | (117.65 M) | ||||
| Net Income | (118.51 M) | ||||
| Cash And Equivalents | 157.51 M | ||||
| Cash Per Share | 2.93 X | ||||
| Total Debt | 43.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.32 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (92.08 M) | ||||
| Earnings Per Share | (1.75) X | ||||
| Market Capitalization | 16.68 M | ||||
| Total Asset | 125.84 M | ||||
| Retained Earnings | (684.75 M) | ||||
| Working Capital | 90.57 M | ||||
| Current Asset | 108.93 M | ||||
| Current Liabilities | 5.27 M | ||||
About Cara Therapeutic Performance
By analyzing Cara Therapeutic's fundamental ratios, stakeholders can gain valuable insights into Cara Therapeutic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cara Therapeutic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cara Therapeutic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 166.77 | 118.27 | |
| Return On Tangible Assets | (0.94) | (0.89) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (0.94) | (0.89) | |
| Return On Equity | (2.08) | (1.97) |
Things to note about Cara Therapeutic performance evaluation
Checking the ongoing alerts about Cara Therapeutic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cara Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cara Therapeutic generated a negative expected return over the last 90 days | |
| Cara Therapeutic has some characteristics of a very speculative penny stock | |
| Cara Therapeutic has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (56.14 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cara Therapeutic has a strong financial position based on the latest SEC filings | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Cara Q3 Earnings Snapshot |
- Analyzing Cara Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cara Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Cara Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cara Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cara Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cara Therapeutic's stock. These opinions can provide insight into Cara Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |